This paper is only available as a PDF. To read, Please Download here.
In the past decade, increasing attention is being given to more systematic and quantitative
ways to evaluate explicitly the impact of diseases and medical interventions on quality
of life. A substantial part of this research pertains to the field of cancer where
cure is not always possible and treatments are mostly intrusive. In recent years it
has become more acceptable to include a quality of life (mostly as a secondary) outcome
measure in cancer clinical trials. It is for this reason that quality of life as an
outcome measure was discussed at the conference on ‘Cancer Research and Treatment
— Towards the 21st Century’ in Heidelberg. The presentation highlighted the present
situation, current problems, and future perspectives of quality of life research in
cancer care within Europe. The following text is a section from ‘A Practical Guide to EORTC Studies’, which describes some of the issues involved in the use of quality of life assessment
in clinical trials from the perspective of the EORTC.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Footnotes
This paper is reprinted from A Practical Guide to EORTC Studies edited by P. Therasse, Brussels, EORTC Data Centre, 1996, with the permission of the EORTC.
Identification
Copyright
© 1997 Published by Elsevier Inc.
